Actively Recruiting

Phase 2
Age: 50Years +
All Genders
NCT05626114

A Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (GAlette); Adaptive Optics (AO) Retinal Imaging Substudy in Association With Study GR44251

Led by Genentech, Inc. · Updated on 2026-04-21

60

Participants Needed

17

Research Sites

414 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This study will evaluate the success and safety of subretinal surgical delivery as well as the preliminary activity of OpRegen in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). All endpoints are assessed for the study eye unless otherwise indicated. The substudy will evaluate the operational feasibility and scientific interpretability of incorporating AO retinal imaging using the EarlySight Cellularis® Discovery device. Participants who have fulfilled the eligibility requirements for the parent study and meet the substudy's eligibility criteria will have the option to participate in the substudy. The EarlySight Cellularis® Discovery device will be used only as an assessment tool and data obtained from this device will not be used to guide clinical care or influence clinical outcomes for participants.

CONDITIONS

Official Title

A Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (GAlette); Adaptive Optics (AO) Retinal Imaging Substudy in Association With Study GR44251

Who Can Participate

Age: 50Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Ability to undergo a vitreoretinal surgical procedure under monitored anesthesia care
  • Diagnosis of geographic atrophy secondary to age-related macular degeneration
  • Best corrected visual acuity (BCVA) score 29 letters and 240 letters in the study eye as assessed by Early Treatment Diabetic Retinopathy Study (ETDRS)
  • Pseudophakic (study eye)
Not Eligible

You will not qualify if you...

  • Pregnancy or breastfeeding
  • History of cognitive impairment or dementia
  • Any systemic disease or treatment that could affect clinical status or increase risk as judged by the investigator
  • Any current or history of ocular disease other than geographic atrophy that may affect macula assessment
  • History of retinal detachment
  • History of vitrectomy, glaucoma-filtering surgery, or corneal transplant
  • Uncontrolled or advanced glaucoma
  • Any cataract or intraocular surgery within 3 months prior to OpRegen delivery
  • History of ocular or intraocular conditions contraindicating investigational drug use or increasing treatment risk
  • Any existing posterior segment device or implant
  • Past history of seizures or epilepsy except a single febrile seizure in childhood

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 17 locations

1

Retina-Vitreous Associates Medical Group

Beverly Hills, California, United States, 90211

Actively Recruiting

2

Retinal Consultants Medical Group

Sacramento, California, United States, 95825

Actively Recruiting

3

West Coast Retina

San Francisco, California, United States, 94109-5520

Actively Recruiting

4

Retina Vitreous Associates of Florida

St. Petersburg, Florida, United States, 33711

Actively Recruiting

5

The Retina Care Center

Baltimore, Maryland, United States, 21209-2219

Actively Recruiting

6

The Retina Institute

St Louis, Missouri, United States, 63128-1729

Actively Recruiting

7

Sierra Eye Associates

Reno, Nevada, United States, 89502-1605

Actively Recruiting

8

Duke Eye Center

Durham, North Carolina, United States, 27705-4699

Actively Recruiting

9

Cincinnati Eye Institute

Blue Ash, Ohio, United States, 45242-5537

Actively Recruiting

10

Mid Atlantic Retina

Philadelphia, Pennsylvania, United States, 19107-5109

Actively Recruiting

11

Tennessee Retina PC

Nashville, Tennessee, United States, 37203-1513

Actively Recruiting

12

Austin Clinical Research, LLC

Austin, Texas, United States, 78750-2298

Actively Recruiting

13

Retina Consultants of Texas

Bellaire, Texas, United States, 77401

Actively Recruiting

14

Piedmont Eye Center

Lynchburg, Virginia, United States, 24502-4271

Actively Recruiting

15

Spokane Eye Clinical Research;Spokane Eye Surgery Center

Spokane, Washington, United States, 99204

Actively Recruiting

16

Hadassah MC

Jerusalem, Israel, 9112001

Actively Recruiting

17

Tel Aviv Sourasky MC

Tel Aviv, Israel, 6423906

Actively Recruiting

Loading map...

Research Team

R

Reference Study ID Number: GR44251 https://forpatients.roche.com/

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here